T cell-directed immune therapies for multiple myeloma: chimeric antigen receptor-modified T cells and bi-specific T cell-engaging agents
Therapeutic monoclonal antibodies targeting SLAMF7 and CD38 are the first classes of targeted immune therapies approved for multiple myeloma, a cancer of plasma cells. These agents are effective, particularly in combination with immunomodulatory drugs lenalidomide and pomalidomide. The next generation of myeloma immunotherapy under investigation consists of T cell-directed strategies designed to promote cytotoxic activity against myeloma cells, as embodied by chimeric antigen receptor-modified T (CAR-T) cells and bi-specific T cell engaging agents.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Deepu Madduri, Madhav V. Dhodapkar, Sagar Lonial, Sundar Jagannath, Hearn Jay Cho Source Type: research
More News: Cancer | Cancer & Oncology | Hematology | Immunotherapy | Leukemia | Lymphoma | Myeloma | Revlimid